Abstract
Although molecularly targeted therapy with imatinib has improved treatments of chronic myeloid leukemia (CML), clinical resistance gradually develops in patients with accelerated or blast phase CML. The inability of imatinib to cure CML suggests that inactivation of BCR-ABL kinase activity alone is not sufficient to control the disease. Aberrant STAT signaling and constitutive STAT5 or STAT3 activation are frequently found in both acute and chronic leukemia. Constitutive activation of STAT5 and STAT3 are associated with imatinib resistance on leukemia cells. Development of drugs targeting SH2 domains of STAT5 and STAT3 provides a novel strategy for the treatment of the imatinib-resistant CML. Here, molecular docking and molecular dynamics simulations were used to investigate the interactions of the drugs targeting STAT3 and STAT5 receptors at molecular level. The calculated binding free energies are consistent with the ranking of the experimental affinities and our simulations also explained their differences in binding energy. Then virtual screening based on molecular docking and molecular dynamics was applied to screen a set of ~1500 compounds for dual inhibitors of the SH2 domains of STAT5 and STAT3. Three top score compounds obtained in virtual screening were compound 660, 304, and 561. Results show that the three predicted dual-inhibitors are well fitted within the two binding domains and are predicted to present improved STAT5 and STAT3 SH2 inhibitory activity.
Similar content being viewed by others
References
An X, Tiwari AK, Sun Y, Ding PR, Ashby CR, Chen ZS (2010) Leuk Res 34:1255–1268
Bauer S, Romvari E (2009) Clin J Oncol Nurs 13:523–534
Vaidya S, Ghosh K, Vundinti BR (2011) Eur J Haematol 87:381–393
Pene-Dumitrescu T, Smithgall TE (2010) J Biol Chem 285:21446–21457
Noor SM, Bell R, Ward AC (2011) Crit Rev Oncol Hematol 78:33–44
O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T (2003) N Engl J Med 348:994–1004
Hochhaus A (2006) Ann Oncol 17:274–279
Mahon FX, Deininger MWN, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV (2000) Blood 96:1070–1079
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Sci Signal 293:876–880
Bixby D, Talpaz M (2010) Leukemia 25:7–22
Roychowdhury S, Talpaz M (2011) Blood Rev 25:279–290
Benekli M, Baer MR, Baumann H, Wetzler M (2003) Blood 101:2940–2954
Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, Hochhaus A, Neubauer A, Burchert A (2007) Blood 109:2147–2155
Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Hölbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G (2011) Blood 117:3409–3420
Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA (2008) Mol Cancer Ther 7:3169–3175
Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G (2010) EMBO Mol Med 2:98–110
Leeman RJ, Lui VWY, Grandis JR (2006) Expert Opin Biol Ther 6:231–241
Darnell JE (2005) Nat Med 11:595–596
McMurray JS (2008) Biopolymers 90:69–79
Nelson EA, Sharma SV, Settleman J, Frank DA (2011) Oncotarget 2:518–524
Schust J, Sperl B, Hollis A, Mayer TU, Berg T (2006) Chem Biol 13:1235–1242
Hao W, Hu Y, Niu C, Huang X, Chang CPB, Gibbons J, Xu J (2008) Bioorg Med Chem Lett 18:4988–4992
Song H, Wang R, Wang S, Lin J (2005) Proc Natl Acad Sci U S A 102:4700–4705
Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip MLR, Jove R, McLaughlin MM, Lawrence NJ (2007) Proc Natl Acad Sci U S A 104:7391–7396
Schust J, Berg T (2004) Anal Biochem 330:114–118
Shahani VM, Yue P, Haftchenary S, Zhao W, Lukkarila JL, Zhang X, Ball D, Nona C, Gunning PT, Turkson J (2010) ACS Med Chem Lett 2:79–84
Bhasin D, Cisek K, Pandharkar T, Regan N, Li C, Pandit B, Lin J, Li PK (2008) Bioorg Med Chem Lett 18:391–395
Lin L, Deangelis S, Foust E, Fuchs J, Li C, Li PK, Schwartz EB, Lesinski GB, Benson D, Lu J (2010) Mol Cancer 9:217
Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D (2010) Neoplasia 12:39–50
Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, Laudano A, Sebti S, Hamilton AD, Jove R (2001) J Biol Chem 276:45443–45455
Bharti AC, Donato N, Aggarwal BB (2003) J Immunol 171:3863–3871
Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A (1996) Nature 379:645–648
Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R (2006) Oncogene 26:2435–2444
Faderl S, Ferrajoli A, Harris D, Van Q, Priebe W, Estrov Z (2005) Anticancer Res 25:1841–1850
Müller J, Sperl B, Reindl W, Kiessling A, Berg T (2008) Chembiochem 9:723–727
Tanimoto TT (1957) Nov 17:1957
Zhu T, Cao S, Su P-C, Patel R, Shah D, Chokshi HB, Szukala R, Johnson ME, Hevener KE (2013) J Med Chem 56:6560–6572
Becker S, Groner B, Muller CW (1998) Nature 394:145–151
Neculai D, Neculai AM, Verrier S, Straub K, Klumpp K, Pfitzner E, Becker S (2005) J Biol Chem 280:40782–40787
Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) J Comput Chem 19:1639–1662
Gasteiger J, Marsili M (1980) Tetrahedron 36:3219–3228
Hou T, Wang J, Li Y, Wang W (2011) J Chem Inf Model 51:69–82
Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, Merz KM, Onufriev A, Simmerling C, Wang B, Woods RJ (2005) J Comput Chem 26:1668–1688
Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) J Comput Chem 25:1157–1174
Ryckaert JP, Ciccotti G, Berendsen HJC (1977) J Chem Phys 23:327–341
Darden T, York D, Pedersen L (1993) J Chem Phys 98:10089
Yang Y, Shen Y, Li S, Jin N, Liu H, Yao X (2012) Mol BioSyst 8:3049–3060
Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, Haura E, Sebti S, Hamilton AD, Jove R (2004) Mol Cancer Ther 3:261–269
Park IH, Li C (2010) J Mol Recognit 24:254–265
Klebe G (2009) The foundations of protein–ligand interaction In: From molecules to medicines. Springer, Heidelberg, pp 79-101
Wang J, Morin P, Wang W, Kollman PA (2001) J Am Chem Soc 123:5221–5230
Barakat K, Mane J, Friesen D, Tuszynski J (2010) J Mol Graph Model 28:555–568
Page BD, Khoury H, Laister RC, Fletcher S, Vellozo M, Manzoli A, Yue P, Turkson J, Minden MD, Gunning PT (2012) J Med Chem 55:1047–1055
Zhang X, Yue P, Fletcher S, Zhao W, Gunning PT, Turkson J (2010) Biochem Pharmacol 79:1398–1409
Fletcher S, Page BD, Zhang X, Yue P, Li ZH, Sharmeen S, Singh J, Zhao W, Schimmer AD, Trudel S (2011) ChemMedChem 6:1459–1470
Shi C, Yu R, Shao S, Li Y (2012) J Mol Model 19:871–878
Yu R, Craik DJ, Kaas Q (2011) PLoS Comput Biol 7:e1002011
Velazquez-Campoy A, Todd MJ, Freire E (2000) Biochemistry 39:2201–2207
Li L, Li Y, Zhang L, Hou T (2012) J Chem Inf Model 52:2715–2729
Luque I, Freire E (2002) Proteins Struct Funct Bioinforma 49:181–190
Leavitt S, Freire E (2001) Curr Opin Struct Biol 11:560–566
Acknowledgments
The authors gratefully acknowledge a grant support from the Scientific Research Foundation for Returned Overseas Chinese Scholars and the State Education Ministry.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shao, S., Yu, R., Yu, Y. et al. Dual-inhibitors of STAT5 and STAT3: studies from molecular docking and molecular dynamics simulations. J Mol Model 20, 2399 (2014). https://doi.org/10.1007/s00894-014-2399-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00894-014-2399-x